Cargando…

Formalizing drug indications on the road to therapeutic intent

Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Stuart J, Oprea, Tudor I, Ursu, Oleg, Bologa, Cristian G, Zaveri, Amrapali, Holmes, Jayme, Yang, Jeremy J, Mathias, Stephen L, Mani, Subramani, Tuttle, Mark S, Dumontier, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259666/
https://www.ncbi.nlm.nih.gov/pubmed/29016968
http://dx.doi.org/10.1093/jamia/ocx064
_version_ 1783374729465298944
author Nelson, Stuart J
Oprea, Tudor I
Ursu, Oleg
Bologa, Cristian G
Zaveri, Amrapali
Holmes, Jayme
Yang, Jeremy J
Mathias, Stephen L
Mani, Subramani
Tuttle, Mark S
Dumontier, Michel
author_facet Nelson, Stuart J
Oprea, Tudor I
Ursu, Oleg
Bologa, Cristian G
Zaveri, Amrapali
Holmes, Jayme
Yang, Jeremy J
Mathias, Stephen L
Mani, Subramani
Tuttle, Mark S
Dumontier, Michel
author_sort Nelson, Stuart J
collection PubMed
description Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent.
format Online
Article
Text
id pubmed-6259666
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62596662018-12-03 Formalizing drug indications on the road to therapeutic intent Nelson, Stuart J Oprea, Tudor I Ursu, Oleg Bologa, Cristian G Zaveri, Amrapali Holmes, Jayme Yang, Jeremy J Mathias, Stephen L Mani, Subramani Tuttle, Mark S Dumontier, Michel J Am Med Inform Assoc Perspective Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent. Oxford University Press 2017-11 2017-07-17 /pmc/articles/PMC6259666/ /pubmed/29016968 http://dx.doi.org/10.1093/jamia/ocx064 Text en © The Author 2017. Published by Oxford University Press on behalf of the American Medical Informatics Association. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Perspective
Nelson, Stuart J
Oprea, Tudor I
Ursu, Oleg
Bologa, Cristian G
Zaveri, Amrapali
Holmes, Jayme
Yang, Jeremy J
Mathias, Stephen L
Mani, Subramani
Tuttle, Mark S
Dumontier, Michel
Formalizing drug indications on the road to therapeutic intent
title Formalizing drug indications on the road to therapeutic intent
title_full Formalizing drug indications on the road to therapeutic intent
title_fullStr Formalizing drug indications on the road to therapeutic intent
title_full_unstemmed Formalizing drug indications on the road to therapeutic intent
title_short Formalizing drug indications on the road to therapeutic intent
title_sort formalizing drug indications on the road to therapeutic intent
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259666/
https://www.ncbi.nlm.nih.gov/pubmed/29016968
http://dx.doi.org/10.1093/jamia/ocx064
work_keys_str_mv AT nelsonstuartj formalizingdrugindicationsontheroadtotherapeuticintent
AT opreatudori formalizingdrugindicationsontheroadtotherapeuticintent
AT ursuoleg formalizingdrugindicationsontheroadtotherapeuticintent
AT bologacristiang formalizingdrugindicationsontheroadtotherapeuticintent
AT zaveriamrapali formalizingdrugindicationsontheroadtotherapeuticintent
AT holmesjayme formalizingdrugindicationsontheroadtotherapeuticintent
AT yangjeremyj formalizingdrugindicationsontheroadtotherapeuticintent
AT mathiasstephenl formalizingdrugindicationsontheroadtotherapeuticintent
AT manisubramani formalizingdrugindicationsontheroadtotherapeuticintent
AT tuttlemarks formalizingdrugindicationsontheroadtotherapeuticintent
AT dumontiermichel formalizingdrugindicationsontheroadtotherapeuticintent